US Patent Issued to Rigel Pharmaceuticals on Feb. 3 for "RET inhibitor for use in treating cancer having a RET alteration" (Massachusetts Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,539,303, issued on Feb. 3, was assigned to Rigel Pharmaceuticals Inc. (South San Francisco, Calif.).

"RET inhibitor for use in treating cancer having a RET alteration" was invented by Erica Evans Raab (Cambridge, Mass.) and Beni B. Wolf (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily."

The patent wa...